| 摘要 |
<p>The invention provides metabolites of the compound 2-amino-N-Ä2-(3a(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-Ä4,3-cÜpyridin-5-yl)-1-(R)-benzyl-oxymethyl-2-oxo-ethylÜ-i sobutyramide, the racemic-diastereomeric mixtures and optical isomers thereof, the prodrugs thereof, and the pharmaceutically acceptable salts of the metabolites, racemic-diastereomeric mixtures, optical isomers, and prodrugs; to pharmaceutical compositions thereof; and to methods of using the metabolites and the compositions in the treatment of diseases associated with reduced levels of growth hormone. <??>The invention further provides a kit comprising a metabolite of the compound 2-amino-N-Ä2-(3a(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-Ä4,3-cÜpyridin-5-yl)-1-(R)-benzyl-oxymethyl-2-oxo-ethylÜ-i sobutyramide a racemic-diastereomeric mixture or optical isomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt of the metabolite, racemic-diastereomeric mixture, optical isomers, or prodrug, and a pharmaceutically acceptable carrier, vehicle or diluent in a first unit dosage form; estrogen, progesterone, Premarin TM , or a bisphosphonate compound, preferably alendronate, and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and a container.</p> |
